Skip to main content
OpenTrials

Clinical trial condition

HER2/Neu Negative

Explore clinical trials studying HER2/Neu Negative. Study availability and eligibility vary by location and protocol.

55 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

HER2/Neu Negative trial results

Completed

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

NCT00390455

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Positive, +11 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Arroyo Grande Community Arroyo Grande, California, United States
  • PCR Oncology Arroyo Grande, California, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
View all 368 locations
View Trial Details
Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

NCT01964924

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +11 more
Locations
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
View Trial Details
Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT00892736

Conditions
Adnexal Diseases, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, +48 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
View Trial Details
Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

NCT01145430

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +30 more
Locations
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
  • Mount Sinai Hospital New York, United States
  • Columbia University/Herbert Irving Cancer Center New York, United States
  • Weill Medical College of Cornell University New York, United States
View Trial Details

Related conditions